1 source · first reported 4d ago
The Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical has equipped the Joint Force with a device to counter nerve agent attacks, achieving Full Operational Capability in March 2026. The device is approved by the U.S. Food and Drug Administration. This development enhances warfighter safety and mission readiness.
This device provides critical protection to warfighters against nerve agent attacks, enhancing their safety and effectiveness in combat environments. The achievement of Full Operational Capability marks a significant milestone in the development and deployment of this lifesaving technology.
How this story unfolded across sources, oldest first.